You are here

Article Text

Article menu
Unexpected outcome (positive or negative) including adverse drug reactions
Metformin-induced cholangiohepatitis
  1. Raja Shekhar Reddy Sappati Biyyani1,
  2. Smitha Battula2,
  3. Christopher A Erhardt3,
  4. Khalil Korkor2,3,4
  1. 1
    Case Western Reserve University @ MetroHealth Medical Center, Hospital Medicine, 2500 MetroHealth Dr, Cleveland, Ohio, 44138, USA
  2. 2
    Gastroenterology of Canton Inc, 4124 Munson Rd NW, Canton, Ohio, 44718, USA
  3. 3
    Mercy Medical Center, 1320 Mercy Dr NW, Canton, Ohio, 44708, USA
  4. 4
    NEOUCOM, Gastroenterology, Gastroenterology of Canton Inc, 4124 Munson St NW, Canton, Ohio, 44718, USA
  1. Raja Shekhar Reddy Sappati Biyyani, rsappati{at}hotmail.com

Summary

Drug-induced cholangiohepatitis accounts for 20–50% of non-viral chronic hepatitis cases. Metformin is the most commonly prescribed oral anti-diabetic drug from the biguanide class used in treatment of overweight and obese type 2 diabetes mellitus patients. Metformin-induced cholangiohepatitis with marked elevations in serum liver transaminases and intrahepatic cholestasis has been infrequently reported. Here, we report a case of acute cholangiohepatitis after initiation of metformin treatment.

https://doi.org/10.1136/bcr.09.2008.0950

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Competing interests: none.